Mineralys Therapeutics(NASDAQ) MLYS

Mineralys Therapeutics, Inc. makes pills for people with high blood pressure. These treatments help patients when other medicines do not work. The company targets a hormone that harms the heart and kidneys.

Managing Uncontrolled Blood Pressure

• Lorundrostat: Experimental pill designed to block a hormone that causes high blood pressure; currently under review for approval in the United States.
• Hypertension Program: Clinical studies focused on patients with uncontrolled high blood pressure who do not respond to standard treatments.
• Kidney Treatment: Potential application for chronic kidney disease where high hormone levels contribute to organ damage.

Strategic Moves for Growth

• Submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) in December 2025 for its lead treatment.
• Reached an agreement in June 2026 to remove future royalty payments by paying a partner $200 million upfront.
• Entered a $500 million loan agreement in June 2026 to provide funding through the potential product launch.
• Completed a public stock offering in June 2026 that generated approximately $143.6 million in net proceeds.

A Precision Approach to Medicine

Mineralys focuses on aldosterone synthase, which is an enzyme that regulates a hormone linked to heart and kidney damage. By targeting this specific enzyme, the company aims to provide a more precise treatment for the 30% of hypertension patients with dysregulated hormone levels.

Checking the Balance Sheet

• Cash, cash equivalents, and investments totaled $661.4 million as of June 30, 2026.
• Net loss was $280.4 million for the six-month period ended June 30, 2026, compared to $85.5 million for the same period in 2025.
• Research and development expenses reached $245.7 million for the six-month period ended June 30, 2026.
• Accumulated deficit grew to $737.6 million as of June 30, 2026, reflecting the costs of clinical trials and regulatory activities.
• Market capitalization was $2.3 billion for the quarter ended June 30, 2026, up 158.1% year over year.

Bottom Line

Mineralys has transitioned from a research-focused startup to a pre-commercial company preparing for its first major product launch. Its recent strategy centers on securing full ownership of its lead drug and building the significant capital required to enter the global healthcare market.